Polymeric Drug Conjugates Modular Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of targeted drug conjugates, particularly antibody-drug conjugates (ADCs), is hindered by the complexity of chemical linkers, leading to a need for potent therapeutics with a high therapeutic index and efficient delivery to specific cells like tumor cells while minimizing side effects.
Innovation Solution
The development of dimeric and polymeric biologically active compounds with spacing groups, including linkers and targeting moieties, that enable selective delivery of biologically active moieties to specific cells, such as tumor cells, through covalent linkage and optional use of fluorescent or colored dyes for enhanced targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemical linkers are used in ADC construction, then drug delivery to target cells is achieved, but the complexity of the conjugate increases significantly
Solution Approach 1:
The patent divides the conjugate into modular components: a core structure with multiple identical or similar biologically active moieties attached through standardized linkers. This segmentation allows independent optimization of each component and simplifies the overall construction process while maintaining effective drug delivery to target cells.
Solution Approach 2:
The patent employs universal linker structures that can be used across different conjugate designs. The standardized core structure with multiple attachment points provides a multi-functional platform that can accommodate various biologically active moieties, reducing the need for custom-designed complex linkers for each application.
2Reliability
If multiple biologically active moieties are included in a single compound, then therapeutic efficacy is enhanced, but the structural complexity increases
Solution Approach 1:
The patent merges multiple biologically active moieties into a single conjugate structure that binds to one target cell. The core structure serves as a unified platform that combines multiple therapeutic agents, enhancing efficacy through synergistic or additive effects while presenting a single binding entity to the target cell.
Solution Approach 2:
The conjugate functions as a composite structure combining multiple biologically active moieties with a core scaffold and linker systems. This composite approach allows integration of different therapeutic functions (e.g., cytotoxic agents, imaging agents, or different mechanisms of action) within a single molecular entity, improving therapeutic efficacy while managing structural complexity through systematic design.
Data Source
AI summary
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, La, Lb, L1, L2, L3, M, m, and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.